Health & biology · 2017

AAV gene therapy approved

Luxturna restored useful vision to people with an inherited retinal disease.

Luxturna, delivering a working RPE65 gene by adeno-associated virus, was the first in vivo gene therapy approved in the US in December 2017. Zolgensma for spinal muscular atrophy followed in 2019.

See it in the living tree Wikipedia

Arcs above join it to what it stood on, arcs below to what it led to. The bar places this stretch on the tree's whole timeline.

What it built on 1

Gene therapy 1990

What it led to 3

Gene therapy slows Huntington's 2025
Routine in-body gene editing ~2032
Therapies that slow ageing ~2040

Related measurements

The dashed line marks when it first worked.

Cost to sequence a human genome Latest: 525 $ (2022) Source: Our World in Data